• Aucun résultat trouvé

[PDF] Top 20 DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.

Has 10000 "DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects." found on our website. Below are the top 20 most common "DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.".

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.

... adherence to, and optimizing the benefits of therapy [15, ...far from being additive and the final results, as far as the primary endpoint was concerned (HbA1c reduction at week 24), were somewhat ... Voir le document complet

37

Type 2 diabetes mellitus and osteoarthritis

Type 2 diabetes mellitus and osteoarthritis

... receiving combination NSAIDs and metformin therapy had lower joint replacement surgery rates than those without metformin (adjusted HR = ...able to a reduction in pro-in flammatory factors associated ... Voir le document complet

12

Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.

Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.

... increase in endogenous glucose production and thereby enhance the glucose-lowering ability of SGLT2i while reducing the risk of ketoacidosis, although this remains to be proven. Beyond a glucose-lowering effect, ... Voir le document complet

44

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

... opportunity to review our concept of how best to treat type 2 ...other type of antidiabetic ...opportunity to test novel combinations of antidiabetic drugs targeting persistent ... Voir le document complet

3

Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial

Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial

... designed to verify whether the combined use of these two therapies can play an additive role in mitigating micro- and macrovascular ...basis for clinical studies with hard endpoints, EXCEED was ... Voir le document complet

12

Canagliflozin: A Review in Type 2 Diabetes.

Canagliflozin: A Review in Type 2 Diabetes.

... Introduction Type 2 diabetes (T2D) is a chronic progressive metabolic disease characterized by hyperglycaemia, due to insulin resistance/insufficient insulin production [ 1 ...goal, for ... Voir le document complet

20

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.

... remain to be investigated in adequately powered, prospective, controlled clinical ...No clinical trial directly compared the efficacy and safety of these once weekly GLP-1 RAs but each of three ... Voir le document complet

32

S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization

S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization

... Reactive Oxygen Species and quinone reductase 2: Mitochondrial respiration in liver and 535. brain[r] ... Voir le document complet

59

Endoplasmic reticulum stress mediates resistance to BCL-2 inhibitor in uveal melanoma cells

Endoplasmic reticulum stress mediates resistance to BCL-2 inhibitor in uveal melanoma cells

... archive for the deposit and dissemination of sci- entific research documents, whether they are pub- lished or ...come from teaching and research institutions in France or abroad, or from public or ... Voir le document complet

22

Crystal Structures of Fumarate Hydratases from Leishmania major in a Complex with Inhibitor 2-Thiomalate

Crystal Structures of Fumarate Hydratases from Leishmania major in a Complex with Inhibitor 2-Thiomalate

... binds to class I LmFH-1 and LmFH-2 through the coordination of its thiol group to the unique Fe of the catalytic [4Fe-4S] ...strongly to soft base such as thiol group. We were not expecting ... Voir le document complet

11

Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.

Towards a genotype-based approach for a patient-centered pharmacologic therapy of type 2 diabetes.

... resistant to the action of DPP- 4 ...in clinical practice compared to sulfonylureas ...of type 2 diabetes ...known diabetes risk locus, not only affects ... Voir le document complet

5

Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non‑obese type 2 diabetic Goto‑Kakizaki rats

Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non‑obese type 2 diabetic Goto‑Kakizaki rats

... responds to several cellular processes and external stress signaling, such as cell differentiation, cell proliferation, inflammation and cells death ...MAPK inhibitor is an effective ...selective ... Voir le document complet

15

Pharmacological prevention of type 2 diabetes.

Pharmacological prevention of type 2 diabetes.

... of diabetes by early treatment and prevention is clearly of pivotal ...mainstay for the prevention of T2DM given the remarkable reduction in the incidence of T2DM, the prolonged benefits, the demonstrable ... Voir le document complet

46

Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type 1: Implications for clinical trials

Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type 1: Implications for clinical trials

... referred to as PAI-1-stab, harboring the mutations Asnl50His, Lysl54Thr, Gln301Pro, Gln319Leu, and Met354Ile and demonstrating a functional half-life of approximately 150 hours, was produced as described 21 and ... Voir le document complet

10

Enhancement of the Inhibitor Efficiency of 4-Phenyl-1, 2-dithiol-3-thione on Corrosion of Mild Steel for 20% Sulphuric Acid.

Enhancement of the Inhibitor Efficiency of 4-Phenyl-1, 2-dithiol-3-thione on Corrosion of Mild Steel for 20% Sulphuric Acid.

... increases with increasing of the PDTT concentration. The inhibitor efficiencies determined by weight loss, Tafel polar- ization and EIS methods are in reasonable agreement. Based on the polarization results, the ... Voir le document complet

6

Les inhibiteurs de la dipeptidyl peptidase-IV (DPP-IV)‎ : place dans la prise en charge du diabète de type 2

Les inhibiteurs de la dipeptidyl peptidase-IV (DPP-IV)‎ : place dans la prise en charge du diabète de type 2

... archive for the deposit and dissemination of sci- entific research documents, whether they are pub- lished or ...come from teaching and research institutions in France or abroad, or from public or ... Voir le document complet

162

Adsorption of 2-mercaptobenzimidazole Corrosion Inhibitor on Copper: DFT Study on Model Oxidized Interfaces

Adsorption of 2-mercaptobenzimidazole Corrosion Inhibitor on Copper: DFT Study on Model Oxidized Interfaces

... likely to chemically bond with the copper surface atoms. For MBIH ...groups to the DOS, which is visible in the energies range [ ...contribution for the two nitrogen atoms, due to the ... Voir le document complet

15

Targeting the AMPK pathway for the treatment of Type 2 diabetes.

Targeting the AMPK pathway for the treatment of Type 2 diabetes.

... Benoît Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie Hébrard, Chloé Amouyal, et al... Tar- geting the AMPK pathway for the treatment of Type 2 diabetes...[r] ... Voir le document complet

3

Job strain as a risk factor for type 2 diabetes: a pooled analysis of 124,808 men and women.: Job Strain and Incident Type 2 Diabetes

Job strain as a risk factor for type 2 diabetes: a pooled analysis of 124,808 men and women.: Job Strain and Incident Type 2 Diabetes

... of type 2 diabetes varied between the ...standard, to all participants who had not already been diagnosed with diabetes over the follow-up ...able to report on both diagnosed and ... Voir le document complet

27

Large triglyceride-rich lipoproteins from fasting patients with type 2 diabetes activate platelets

Large triglyceride-rich lipoproteins from fasting patients with type 2 diabetes activate platelets

... archive for the deposit and dissemination of sci- entific research documents, whether they are pub- lished or ...come from teaching and research institutions in France or abroad, or from public or ... Voir le document complet

26

Show all 10000 documents...